Benchmark starts Ingredion at Buy, sees ‘compelling entry point’

As previously reported, Benchmark analyst Ben Klieve initiated coverage of Ingredion (INGR) with a Buy rating and $130 price target Ingredion “sits at the intersection of health & wellness and affordability trends,” says the analyst, who sees this positioning it as a durable long-term earnings growth investment. With shares drifting down over the past year as site-specific headwinds compromised FY25 earnings, the firm expects a recovery for that facility together with continuing favorable macro trends to return Ingredion to its historic earnings growth rates in 2027 and sees “a compelling entry point for value and income-oriented investors,” the analyst added.